PE20170142A1 - Proteina de fusion que inhibe angiogenesis o crecimiento y uso de la misma - Google Patents
Proteina de fusion que inhibe angiogenesis o crecimiento y uso de la mismaInfo
- Publication number
- PE20170142A1 PE20170142A1 PE2016001099A PE2016001099A PE20170142A1 PE 20170142 A1 PE20170142 A1 PE 20170142A1 PE 2016001099 A PE2016001099 A PE 2016001099A PE 2016001099 A PE2016001099 A PE 2016001099A PE 20170142 A1 PE20170142 A1 PE 20170142A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- fusion protein
- growth
- same
- inhibiting angiogenesis
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 208000033379 Chorioretinopathy Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 abstract 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 abstract 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 102000058223 human VEGFA Human genes 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000006444 vascular growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se refiere a una proteina de fusion que comprende: a) un fragmento de receptor de VEGF humando que contiene una secuencia de aminoacidos SEQ ID NO:1, SEQ ID NO:3 o SEQ ID NO:5; y b) un fragmento Fc de inmunoglobulina humana tal como Fc de IgG1 de SEQ ID NO:7, Fc de IgG2 de SEQ ID NO:8, Fc de IgG3 de SEQ ID NO:9 y Fc de IgG4 de SEQ ID NO:10. Tambien se refiere a un vector de expresion, una composicion farmaceutica, un metodo de tratamiento y un metodo de preparacion. Dicha proteina inhibe la angiogenesis o crecimiento vascular siendo util en el tratamiento de degeneracion macular relacionada a la edad, retinopatia diabetica, coriorretinopatia, entre otros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410035738 | 2014-01-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170142A1 true PE20170142A1 (es) | 2017-04-02 |
Family
ID=53680846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016001099A PE20170142A1 (es) | 2014-01-25 | 2015-01-23 | Proteina de fusion que inhibe angiogenesis o crecimiento y uso de la misma |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9657084B2 (es) |
| EP (1) | EP3098241B1 (es) |
| JP (1) | JP6071099B1 (es) |
| KR (1) | KR101789501B1 (es) |
| CN (1) | CN104804097B (es) |
| AU (1) | AU2015208482B2 (es) |
| CA (1) | CA2935610C (es) |
| ES (1) | ES2648809T3 (es) |
| IL (1) | IL246528B (es) |
| MX (1) | MX368442B (es) |
| NZ (1) | NZ721607A (es) |
| PE (1) | PE20170142A1 (es) |
| RU (1) | RU2634406C1 (es) |
| UA (1) | UA117045C2 (es) |
| WO (1) | WO2015110067A1 (es) |
| ZA (1) | ZA201604362B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2586459T (lt) | 2005-03-25 | 2017-09-25 | Regeneron Pharmaceuticals, Inc. | Vegf antagonisto kompozicijos |
| SI2364691T1 (sl) | 2006-06-16 | 2013-08-30 | Regeneron Pharmaceuticals, Inc. | Formulacije antagonista VEGF, primerne za intravitrealno dajanje |
| SG10202111177VA (en) | 2011-01-13 | 2021-11-29 | Regeneron Pharma | Use of a vegf antagonist to treat angiogenic eye disorders |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2017084616A1 (en) * | 2015-11-19 | 2017-05-26 | Zhuhai Tairuishang Biopharm Ltd. | Methods and compositions for binding vegf |
| CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
| KR101685532B1 (ko) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
| CN106279435B (zh) * | 2016-08-16 | 2019-06-07 | 新乡医学院 | 靶向VEGF与mucin1的抗肿瘤疫苗、编码基因、表达载体、表达工程菌及应用 |
| WO2019083171A2 (ko) * | 2017-10-26 | 2019-05-02 | 주식회사 큐로진생명과학 | 솔루블 vegfr-1 변이체 cdna를 함유하는 raav를 포함하는 황반변성 치료용 조성물 |
| EP3707721B1 (en) * | 2017-11-10 | 2025-12-03 | Sartorius BioAnalytical Instruments, Inc | Live cell visualization and analysis |
| SMT202200374T1 (it) | 2017-11-30 | 2022-11-18 | Regeneron Pharma | Uso di un antagonista del vegf per trattare disturbi angiogenici dell’occhio |
| EP4495136A3 (en) | 2018-01-26 | 2025-04-23 | The Regents of the University of California | Methods and compositions for treatment of angiogenic disorders using anti-vegf agents |
| WO2019169341A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN114867487A (zh) | 2019-11-25 | 2022-08-05 | 加利福尼亚大学董事会 | 用于眼内新生血管的长效vegf抑制剂 |
| KR20230008830A (ko) | 2020-05-08 | 2023-01-16 | 리제너론 파마슈티칼스 인코포레이티드 | Vegf 트랩 및 미니-트랩 및 안구 장애 및 암의 치료 방법 |
| CN116715749B (zh) * | 2023-03-20 | 2024-04-09 | 吉林大学 | 一种与胶原具有特异结合能力vegf活性抑制蛋白及其制备方法与应用 |
| CN117535299B (zh) * | 2023-10-27 | 2024-12-06 | 北京生物制品研究所有限责任公司 | 分离的核酸分子、重组病毒或其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1608685T3 (da) | 2003-03-28 | 2007-06-11 | Regeneron Pharma | VEGF antagonister til behandlingen af diabetes |
| JP2007529418A (ja) | 2003-05-28 | 2007-10-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆアンタゴニストの使用による角膜移植拒絶を処置する方法 |
| WO2005121176A1 (en) * | 2004-06-08 | 2005-12-22 | Chengdu Kanghong Biotechnologies Co. Ltd | Angiogenesis-inhibiting chimeric protein and the use |
| WO2005123104A2 (en) * | 2004-06-10 | 2005-12-29 | Regeneron Pharmaceuticals, Inc. | Use of vegf inhibitors for the treatment of human cancer |
| CN100471872C (zh) * | 2005-11-04 | 2009-03-25 | 余波 | 包含vegf受体片段的优化融合蛋白质及其医疗应用 |
| US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
| CN101279092B (zh) * | 2007-04-02 | 2010-10-27 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备治疗与血管生成有关的疾病中的应用 |
| CN101838329A (zh) * | 2009-03-18 | 2010-09-22 | 嘉和生物药业有限公司 | 抗血管新生融合蛋白 |
-
2015
- 2015-01-23 KR KR1020167017551A patent/KR101789501B1/ko active Active
- 2015-01-23 RU RU2016126023A patent/RU2634406C1/ru active
- 2015-01-23 JP JP2016544126A patent/JP6071099B1/ja active Active
- 2015-01-23 ES ES15739893.4T patent/ES2648809T3/es active Active
- 2015-01-23 CA CA2935610A patent/CA2935610C/en active Active
- 2015-01-23 CN CN201510036141.3A patent/CN104804097B/zh active Active
- 2015-01-23 PE PE2016001099A patent/PE20170142A1/es unknown
- 2015-01-23 MX MX2016008776A patent/MX368442B/es active IP Right Grant
- 2015-01-23 NZ NZ721607A patent/NZ721607A/en unknown
- 2015-01-23 AU AU2015208482A patent/AU2015208482B2/en active Active
- 2015-01-23 UA UAA201606954A patent/UA117045C2/uk unknown
- 2015-01-23 WO PCT/CN2015/071434 patent/WO2015110067A1/zh not_active Ceased
- 2015-01-23 US US15/109,422 patent/US9657084B2/en active Active
- 2015-01-23 EP EP15739893.4A patent/EP3098241B1/en active Active
-
2016
- 2016-06-28 ZA ZA2016/04362A patent/ZA201604362B/en unknown
- 2016-06-29 IL IL246528A patent/IL246528B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CN104804097A (zh) | 2015-07-29 |
| HK1212716A1 (zh) | 2016-06-17 |
| WO2015110067A1 (zh) | 2015-07-30 |
| EP3098241B1 (en) | 2017-10-25 |
| ES2648809T3 (es) | 2018-01-08 |
| MX2016008776A (es) | 2016-11-08 |
| MX368442B (es) | 2019-10-02 |
| CN104804097B (zh) | 2019-02-22 |
| JP2017505118A (ja) | 2017-02-16 |
| UA117045C2 (uk) | 2018-06-11 |
| US9657084B2 (en) | 2017-05-23 |
| AU2015208482A1 (en) | 2016-07-14 |
| RU2634406C1 (ru) | 2017-10-26 |
| BR112016015187A2 (pt) | 2018-06-05 |
| US20170002056A1 (en) | 2017-01-05 |
| IL246528B (en) | 2018-01-31 |
| CA2935610A1 (en) | 2015-07-30 |
| CA2935610C (en) | 2018-01-02 |
| EP3098241A4 (en) | 2017-03-08 |
| KR101789501B1 (ko) | 2017-10-26 |
| EP3098241A1 (en) | 2016-11-30 |
| AU2015208482B2 (en) | 2017-02-02 |
| KR20160085362A (ko) | 2016-07-15 |
| NZ721607A (en) | 2017-05-26 |
| ZA201604362B (en) | 2017-09-27 |
| JP6071099B1 (ja) | 2017-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170142A1 (es) | Proteina de fusion que inhibe angiogenesis o crecimiento y uso de la misma | |
| JO3658B1 (ar) | بروتينات اندماج | |
| PE20190920A1 (es) | Anticuerpos modificados de union a fcrn humano y metodos de utilizacion | |
| PE20250782A1 (es) | Proteinas de union a antigenos trem2 y usos de estas | |
| CO2019006657A2 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
| PE20161440A1 (es) | Variantes del anticuerpo anti-factor d y sus usos | |
| TW201613958A (en) | MIC-1 fusion proteins and uses thereof | |
| GEP20217326B (en) | Constructs having a sirp-alpha domain or variant thereof | |
| MX356517B (es) | Polipéptidos de fusión de serpina y métodos de uso de los mismos. | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| PE20240015A1 (es) | Proteinas de fusion gdf15 y usos de estas | |
| MX2016016868A (es) | Derivados de exendina-4 como agonistas selectivos del receptor de glucagon. | |
| MX395266B (es) | Composición farmacéutica que contiene, como ingrediente activo, proteína de fusión en la cual péptido tumor-penetrante y el agente anti-angiogénesis están fusionados, para prevenir y tratar cáncer o enfermedades relacionadas con la angiogénesis. | |
| MX2021006017A (es) | Polipeptidos de folistatina y sus usos. | |
| PE20220940A1 (es) | Proteinas quimericas insecticidas novedosas toxicas o inhibidoras de plagas de lepidopteros | |
| PE20171336A1 (es) | Anticuerpos contra tau y sus usos | |
| PE20110771A1 (es) | Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi) | |
| EP4534107A3 (en) | Protein complex by use of a specific site of an immunoglobulin fragment for linkage | |
| PE20131065A1 (es) | Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular | |
| PH12020550927A1 (en) | Therapeutic enzyme fusion protein having novel structure and use thereof | |
| MX377570B (es) | Proteínas de fusión ctla4 para el tratamiento de la diabetes. | |
| BR112017028331A2 (pt) | proteínas de fusão que se ligam a receptores fc humanos | |
| WO2015161267A3 (en) | Humanized and chimeric monoclonal antibodies to cd99 | |
| MX2020006328A (es) | Composición inmunogénica. | |
| EA202090084A1 (ru) | Новый терапевтический ферментный слитый белок и его применение |